Nirsevimab (Beyfortus), an antibody targeting respiratory syncytial virus (RSV), is indicated for newborns and infants to prevent bronchiolitis. Available since September 2023, its widespread use ...

A recently approved immunization drug is helping to limit the severity of a respiratory disease that afflicts young children ...

Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a ...

University of Michigan and Centers for Disease Control and Prevention (CDC) investigators determined that both maternal ...

Respiratory syncytial virus (RSV) is an infectious respiratory disease that can look and sound a lot like a cold, with ...

RSV is the most common cause of hospitalization in infants under 1 year old. The infection can spread to the lungs and cause ...

Infant deaths during a trial of a medicine that protects against respiratory syncytial virus were caused by unrelated factors ...

Seasonal maternal respiratory syncytial virus (RSV) vaccination and nirsevimab for infants demonstrate cost-effectiveness, according to two studies published online Nov. 25 in Pediatrics.

Learn about this vaccine that protects against a common seasonal virus that can sometimes cause severe disease, with info on ...